Details of the Drug

General Information of Drug (ID: DMXY980)

• Drug Name: VU0364770
• Synonyms: 61350-00-3; VU 0364770; VU0364770; N-(3-chlorophenyl)picolinamide; N-(3-chlorophenyl)-2-pyridinecarboxamide; N-(3-chlorophenyl)pyridine-2-carboxamide; CHEMBL556667; 2-Pyridinecarboxamide, N-(3-chlorophenyl)-; AC1LHD0L; GTPL6234; SCHEMBL2530324; cid_836002; KS-00001CNQ; CTK2E1861; DTXSID00356877; MolPort-002-826-420; ZINC362766; HMS3651P19; EX-A1099; BCP19097; s2862; 2565AH; BDBM50293743; AKOS003020541; CS-6072; KB-276111; HY-100588; VU-0364770; N-(3-chloro-phenyl)-pyridine-2-carboxamide; SW219537-1

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 232.66
  Topological Polar Surface Area (xlogp); 2.6
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 2
• Chemical Identifiers:
  Formula: C12H9ClN2O
  IUPAC Name: N-(3-chlorophenyl)pyridine-2-carboxamide
  Canonical SMILES: C1=CC=NC(=C1)C(=O)NC2=CC(=CC=C2)Cl
  InChI: InChI=1S/C12H9ClN2O/c13-9-4-3-5-10(8-9)15-12(16)11-6-1-2-7-14-11/h1-8H,(H,15,16)
  InChIKey: SUYUTNCKIOLMAJ-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 836002
  CAS Number: 61350-00-3
  TTD ID: D0W9VN

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Metabotropic glutamate receptor 4 (mGluR4)	TTICZ1O	GRM4_HUMAN	Modulator (allosteric modulator)	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6234).
• [2] The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J Pharmacol Exp Ther. 2012 Feb;340(2):404-21.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 292).
• [4] Serine-O-phosphate has affinity for type IV, but not type I, metabotropic glutamate receptor. Neuroreport. 1993 Sep;4(9):1099-101.
• [5] Agonist analysis of 2-(carboxycyclopropyl)glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in Chinese hamster ovary cells. Br J Pharmacol. 1992 Oct;107(2):539-43.
• [6] Ligand binding to the amino-terminal domain of the mGluR4 subtype of metabotropic glutamate receptor. J Biol Chem. 1999 Apr 9;274(15):10008-13.
• [7] (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology. 2003 Dec;45(7):895-906.
• [8] Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol. 2003 Mar;138(6):1026-30.
• [9] A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential. FASEB J. 2012 Apr;26(4):1682-93.
• [10] (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology. 2001 Mar;40(3):311-8.